Form 4 holding
10%+ Owner
Acrivon Therapeutics, Inc.
- Security class
- Common Stock
- Shares / value
- 3,848,632
- Estimated value
- $16,741,549
- Report date
- 26 Jun 2023
- Price
- $4.35
- Ownership
- Direct
Chione Ltd
Insider Reports History
- Reporting-owner location
- Larnaca, Cyprus
- Latest reporting-owner signature
-
Chione Limited, by /s/ Shalom Leaf, as attorney-in fact by power of attorney
Source: Latest parsed Forms 3/4/5 signature
- Transaction source note
- Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.
Identity
Names, identifiers, and filing context for this profile.
1 identity field
SEC source record
Original filing metadata and source links for verification.
1 source field
Source evidence
Original filing metadata and source links for verification.
1 source field
Reported holdings for Chione Ltd
Insider Reports Filed by Chione Ltd
4
ACRV
Acrivon Therapeutics, Inc.
- Report period
- 26 Jun 2023
- Transactions
- 1
- Transaction value
- -$207
- Accepted by SEC
- 28 Jun 2023, 15:47
- Role
- 10%+ Owner
- Next action
- Open filing details
4
ACRV
Acrivon Therapeutics, Inc.
- Report period
- 15 Jun 2023
- Transactions
- 1
- Transaction value
- -$24,960
- Accepted by SEC
- 20 Jun 2023, 17:15
- Role
- 10%+ Owner
- Next action
- Open filing details
4
ACRV
Acrivon Therapeutics, Inc.
- Report period
- 12 Jun 2023
- Transactions
- 3
- Transaction value
- -$72,412
- Accepted by SEC
- 14 Jun 2023, 18:33
- Role
- 10%+ Owner
- Next action
- Open filing details
4
ACRV
Acrivon Therapeutics, Inc.
- Report period
- 17 Nov 2022
- Transactions
- 5
- Transaction value
- +$5,000,000
- Accepted by SEC
- 21 Nov 2022, 17:26
- Role
- 10%+ Owner
- Next action
- Open filing details
3/A
ACRV
Acrivon Therapeutics, Inc.
- Report period
- 09 Nov 2022
- Transactions
- 0
- Transaction value
- $0
- Accepted by SEC
- 14 Nov 2022, 20:04
- Role
- 10%+ Owner
- Next action
- Open filing details